Request Your FREE Special Report Today:
"Top 10 Forever Stocks for Creating Wealth"

 





(privacy policy)

Request your FREE Special Report today and you'll
also receive a complimentary 6-month subscription
to our Daily Profit investment newsletter.

Sangamo Biosciences nerve drug fails a mid-stage trial, shares sink 60% in pre-market.

Wyatt Research Staff
November 11, 2008
 print 

See (SGMO).
permalink